Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

104 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: comparison of patients according to their eligibility for major randomized clinical trials.
Zink A, Strangfeld A, Schneider M, Herzer P, Hierse F, Stoyanova-Scholz M, Wassenberg S, Kapelle A, Listing J. Zink A, et al. Among authors: wassenberg s. Arthritis Rheum. 2006 Nov;54(11):3399-407. doi: 10.1002/art.22193. Arthritis Rheum. 2006. PMID: 17075823 Free article.
Impact of patient and disease characteristics on therapeutic success during adalimumab treatment of patients with rheumatoid arthritis: data from a German noninterventional observational study.
Kleinert S, Tony HP, Krause A, Feuchtenberger M, Wassenberg S, Richter C, Röther E, Spieler W, Gnann H, Wittig BM. Kleinert S, et al. Among authors: wassenberg s. Rheumatol Int. 2012 Sep;32(9):2759-67. doi: 10.1007/s00296-011-2033-5. Epub 2011 Aug 6. Rheumatol Int. 2012. PMID: 21822659 Free PMC article.
Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study.
Detert J, Bastian H, Listing J, Weiß A, Wassenberg S, Liebhaber A, Rockwitz K, Alten R, Krüger K, Rau R, Simon C, Gremmelsbacher E, Braun T, Marsmann B, Höhne-Zimmer V, Egerer K, Buttgereit F, Burmester GR. Detert J, et al. Among authors: wassenberg s. Ann Rheum Dis. 2013 Jun;72(6):844-50. doi: 10.1136/annrheumdis-2012-201612. Epub 2012 Jun 27. Ann Rheum Dis. 2013. PMID: 22739990 Clinical Trial.
German guidelines for the sequential medical treatment of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs.
Albrecht K, Krüger K, Wollenhaupt J, Alten R, Backhaus M, Baerwald C, Bolten W, Braun J, Burkhardt H, Burmester GR, Gaubitz M, Gause A, Gromnica-Ihle E, Kellner H, Kuipers J, Krause A, Lorenz HM, Manger B, Nüßlein H, Pott HG, Rubbert-Roth A, Schneider M, Specker C, Schulze-Koops H, Tony HP, Wassenberg S, Müller-Ladner U; German Society of Rheumatology. Albrecht K, et al. Among authors: wassenberg s. Rheumatol Int. 2014 Jan;34(1):1-9. doi: 10.1007/s00296-013-2848-3. Epub 2013 Aug 14. Rheumatol Int. 2014. PMID: 23942828 Review.
Rituximab in patients with rheumatoid arthritis in routine practice (GERINIS): six-year results from a prospective, multicentre, non-interventional study in 2,484 patients.
Wendler J, Burmester GR, Sörensen H, Krause A, Richter C, Tony HP, Rubbert-Roth A, Bartz-Bazzanella P, Wassenberg S, Haug-Rost I, Dörner T. Wendler J, et al. Among authors: wassenberg s. Arthritis Res Ther. 2014 Mar 26;16(2):R80. doi: 10.1186/ar4521. Arthritis Res Ther. 2014. PMID: 24670196 Free PMC article. Clinical Trial.
104 results